Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Hypoxia

Sarcoma

Rhabdomyosarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Signs and Symptoms, Respiratory

Myosarcoma

Soft Tissue Sarcoma

All Drugs and Chemicals

Fluoroazomycin arabinoside

Radiopharmaceuticals

18F-FAZA (F18-Fluoroazomycin Arabinoside) is a radioactive agent developed as a non-invasive probe for the assessment of cellular hypoxia. 18F-FAZA Injection is indicated in a single dose of (5.2 MBq/kg \[0.14 mCi/kg\]) Route/method of administration: intravenous injection.

Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI, MR Spectroscopy \[MRS\]

Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.

18F-FAZA (F18-Fluoroazomycin Arabinoside)

BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.

Blood Oxygen Level Dependent [BOLD] MRI

DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells

Diffusion-Weighted [DW] MRI

MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue

Magnetic Resonance Spectroscopy [MRS]

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI, Magnetic Resonance Spectroscopy (MRS) and 18F-FAZA PET-MRI with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (7-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas: Feasibility Steps Toward Personalized Medicine.

No IPD data will be shared with other researchers

Response will be assessed by measurements of tumor volume, percentage of BOLD signal changes, percentage of tumor necrosis, apparent diffusion coefficient, concentration of high-energy and low-energy phosphates in tumor and necrotic areas and 18F-FAZA uptake.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas	NCT03054792	Rhabdomyosarcom... Non-Rhabdo. Sof...	18F-FAZA (F18-F... Blood Oxygen Le... Diffusion-Weigh... Magnetic Resona...	6 Years - 18 Years	The Hospital for Sick Children
Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas	NCT03054792	Rhabdomyosarcom... Non-Rhabdo. Sof...	18F-FAZA (F18-F... Blood Oxygen Le... Diffusion-Weigh... Magnetic Resona...	6 Years - 18 Years	The Hospital for Sick Children

Spots Global Cancer Trial Database for magnetic resonance spectroscopy [mrs]